Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Diversity: FDA Rejects Calls For Enrollment Mandates

Executive Summary

Requiring that underrepresented populations be enrolled based upon disease prevalence is only way to ensure adequate diversity, some stakeholders say; agency continues to prefer more flexible approach offered by guidance, and PhRMA says mandates would lengthen development timelines for new drugs.

Advertisement

Related Content

FDA Carrots And Sticks Are Best Way To Get Subgroup Data, Advocates Say
FDA Acknowledges More Diverse Subgroup Data Needed In Trials

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel